KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (2017 - 2025)

Historic Shares Outstanding for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $121.7 million.

  • Aquestive Therapeutics' Shares Outstanding rose 3342.9% to $121.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 3342.9%. This contributed to the annual value of $91.4 million for FY2024, which is 3338.63% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Shares Outstanding stood at $121.7 million for Q3 2025, which was up 3342.9% from $99.4 million recorded in Q2 2025.
  • Aquestive Therapeutics' Shares Outstanding's 5-year high stood at $121.7 million during Q3 2025, with a 5-year trough of $36.2 million in Q1 2021.
  • Its 5-year average for Shares Outstanding is $68.3 million, with a median of $61.6 million in 2023.
  • Its Shares Outstanding has fluctuated over the past 5 years, first skyrocketed by 791.68% in 2021, then soared by 6179.35% in 2024.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Shares Outstanding stood at $41.2 million in 2021, then surged by 32.98% to $54.8 million in 2022, then increased by 25.0% to $68.5 million in 2023, then surged by 33.39% to $91.4 million in 2024, then skyrocketed by 33.09% to $121.7 million in 2025.
  • Its last three reported values are $121.7 million in Q3 2025, $99.4 million for Q2 2025, and $99.3 million during Q1 2025.